Placebo + SOC

DRUG5 trials

Sponsors

Boehringer Ingelheim, InflaRx GmbH, Corvus Pharmaceuticals, Inc., 101 Therapeutics, ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Conditions

COVID-19Covid-19Hepatitis C, ChronicSevere COVID-19 PneumoniaSystemic Lupus Erythematosus

Phase 1

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

CompletedNCT00905632

Boehringer IngelheimHepatitis C, Chronic

Start: 2009-05-31Updated: 2016-04-19

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Not yet recruitingNCT06535412

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.Systemic Lupus Erythematosus

Start: 2024-10-10End: 2026-06-10Target: 218Updated: 2024-08-02

Phase 2

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

CompletedNCT04333420

InflaRx GmbHSevere COVID-19 Pneumonia

Start: 2020-03-31End: 2021-12-01Updated: 2023-06-05

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

TerminatedNCT05195749

101 TherapeuticsCOVID-19

Start: 2022-01-13End: 2023-02-14Updated: 2023-02-24

Phase 3

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

TerminatedNCT04734873

Corvus Pharmaceuticals, Inc.Covid-19

Start: 2021-02-25End: 2021-08-18Updated: 2022-09-21

Related Papers

85. Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients

Open Forum Infectious Diseases2025-01-291 citations

Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.

2024-06-284 citations

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.

2023-06-197 citations

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

2022-09-0799 citations

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19

Blood Advances2021-12-0164 citations

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.

2020-09-28149 citations